FDA Brief

Warning letters Drugs

FDA warning letter to

Beijing Xinggu Lvsan Technology Co., Ltd. Formerly known as Beijing Lvsan Technology Co., Ltd.

High riskIssued Oct 5, 2022Posted Oct 18, 2022Center for Drug Evaluation and Research | CDER

FDA cites Beijing Xinggu Lvsan for manufacturing-rule failures and unapproved, misbranded hand sanitizers.

What happened

FDA inspected the drug manufacturing facility from April 11 to 15, 2022 and found CGMP (current good manufacturing practice) failures: no identity testing of incoming components, shared equipment with non-drug industrial products, no microbial testing of finished hand sanitizer batches, no process validation, and weak quality-unit and data records. FDA also found SierraSoft Alcohol Hand Sanitizer and SierraSoft Non-Alcohol Foam Hand Sanitizer were unapproved new drugs and misbranded. FDA placed the firm on Import Alert 66-40 on August 1, 2022.

What FDA found

  1. FDA says the firm did not test incoming components for identity and relied on certificates of analysis from unqualified suppliers.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. FDA says the firm used the same equipment for drugs and non-drug industrial products without adequate cleaning procedures, risking cross-contamination.

    21 CFR 211.67(b)
  3. FDA says the firm did not test each finished hand sanitizer batch for objectionable microorganisms before release.

    21 CFR 211.165(b)
  4. FDA says the firm did not validate hand sanitizer manufacturing processes or identify critical variables such as time.

    21 CFR 211.100(a)
  5. FDA says the quality unit failed to oversee manufacturing; batch records lacked release dates and signatures, lab results were illegible or not attributable, and a food-grade alcohol certificate was supplied for a drug ingredient.

    21 CFR 211.22
  6. FDA says SierraSoft hand sanitizers were unapproved new drugs and misbranded because they did not meet conditions for nonprescription marketing without approval and the alcohol product’s Drug Facts label was not in the required format.

    FD&C Act sections 505(a), 502(c), and 502(ee), 21 U.S.C. 355(a), 352(c), 352(ee)

What FDA wants

FDA asks the firm to correct the violations promptly and provide detailed risk assessments, testing and validation plans, quality-unit remediation, and data-integrity corrective actions. If it intends to resume making drugs for the U.S. market, FDA recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy hand sanitizer from this contract manufacturer
  • US retailers and distributors selling SierraSoft hand sanitizers
  • drugmakers that share equipment with non-drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk